Akums Drugs & Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• Akums Drugs & Pharmaceuticals Ltd reported a 0.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.3%.
• Its expenses for the quarter were up by 3.0% QoQ and 2.7% YoY.
• The net profit decreased 34.0% QoQ and decreased 35.9% YoY.
• The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd stood at 2.66 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Akums Drugs & Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, primarily engaged in the manufacturing and distribution of pharmaceutical products. The company is known for its extensive portfolio of pharmaceutical formulations and active pharmaceutical ingredients (APIs). While specific recent developments are not provided in the data, Akums Drugs & Pharmaceuticals Ltd is generally recognized for its contributions to pharmaceutical manufacturing and has a significant presence in the Indian pharmaceutical sector. The company plays a pivotal role in supplying various pharmaceutical products to both domestic and international markets.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Akums Drugs & Pharmaceuticals Ltd reported a total income of ₹1049.90 crores. This represents a slight decrease of 0.1% compared to the previous quarter (Q1FY26), where the total income was ₹1050.76 crores. When compared to the same quarter in the previous year (Q2FY25), where the total income was ₹1046.56 crores, there is a modest increase of 0.3%. The revenue figures indicate a relatively stable performance in terms of income over the year, with minor fluctuations observed quarterly.

Profitability

For the quarter Q2FY26, the company recorded a Profit Before Tax (PBT) of ₹65.67 crores, which is a decrease of 31.3% from the previous quarter's PBT of ₹95.65 crores. Compared to Q2FY25, where the PBT was ₹91.59 crores, there is a decline of 28.3%. The Profit After Tax (PAT) for Q2FY26 stands at ₹42.69 crores, showing a reduction of 34.0% from Q1FY26's PAT of ₹64.69 crores. Additionally, when compared to Q2FY25's PAT of ₹66.65 crores, there is a decline of 35.9%. The Earnings Per Share (EPS) for Q2FY26 is ₹2.66, down from ₹4.15 in Q1FY26 and ₹4.37 in Q2FY25, marking decreases of 35.9% and 39.1% respectively. These metrics reflect a downward trend in profitability both on a quarterly and yearly basis.

Operating Metrics

The total expenses for Q2FY26 were reported at ₹984.21 crores, reflecting an increase of 3.0% from Q1FY26, where expenses were ₹955.12 crores. Compared to Q2FY25's total expenses of ₹958.66 crores, there is an increase of 2.7%. The tax expense for Q2FY26 was ₹22.98 crores, which indicates a decrease of 25.8% from the previous quarter's tax expense of ₹30.96 crores. When compared to the same period last year, which had a tax expense of ₹24.94 crores, there is a decline of 7.9%. These operating metrics suggest a rise in operational costs over the quarters, while tax expenses have decreased both quarterly and annually.